June 3, 2017 01:45 PM EDT
R&D

J&J’s stel­lar prostate can­cer da­ta sig­nals the like­li­hood of a broad­er mar­ket ap­proval, as Pfiz­er ri­val strug­gles

John Carroll

Editor & Founder

CHICA­GO — J&J will be look­ing to ex­pand its block­buster mar­ket for Zyti­ga (abi­raterone) af­ter post­ing stel­lar da­ta at AS­CO show­ing that the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times